Post by CureDuchenne

“This is really the Holy Grail, to be able to deliver the full-length dystrophin,” said Debra Miller, CEO of CureDuchenne, a nonprofit group that participated in SonoThera’s new financing through a subsidiary, CureDuchenne Ventures. https://lnkd.in/e4wvUxFG